文献速递脑血管病神经重症与神经感染

急性缺血性卒中再灌注治疗前后的早期血压管理

Early blood pressure management in acute ischaemic stroke before and after reperfusion treatment.
PubMed 文献 · Lancet Neurol · 2026-01-01

急性缺血性卒中患者常伴血压升高,既往指南推荐再灌注治疗前将收缩压控制在185 mm Hg以下,但新证据对此提出挑战。INTERACT4、MR-ASAP、RIGHT-2等试验及TRUTH观察性研究提示,再灌注治疗前强化降压与死亡和残疾风险增加相关;成功血管内取栓后血压管理亦受类似证据影响。当前证据强调再灌注治疗前后将收缩压强化降至140 mm Hg以下有害,尚需随机证据明确升高的血压是否应干预或任其自然下降。

要点

  • 再灌注治疗前强化降压至收缩压<140 mm Hg与死亡和残疾风险增加相关。
  • 成功血管内取栓后强化降压亦可能有害,需避免过度降压。
  • 升高的血压是否应干预或任其自然下降,尚需随机证据明确。

核心结论

  • 当前证据强调急性缺血性卒中再灌注治疗前后将收缩压强化降至140 mm Hg以下有害。
  • 尚需随机证据明确升高的血压是否应干预或任其自然下降。

研究设计与样本

  • 综述类文章,汇总INTERACT4、MR-ASAP、RIGHT-2等主要临床试验及TRUTH观察性研究。

主要发现

  • INTERACT4、MR-ASAP、RIGHT-2及TRUTH研究提示再灌注治疗前强化降压与死亡和残疾风险增加相关。
  • 成功血管内取栓后血压管理亦受类似证据影响。
  • 脑缺血机制可能涉及侧支循环和微循环脑血流改变。

关键数值与推荐

  • 既往指南推荐再灌注治疗前收缩压控制在185 mm Hg以下,新证据对此提出挑战。
  • 当前证据强调再灌注治疗前后收缩压强化降至140 mm Hg以下有害。

临床怎么用

  • 再灌注治疗前后应避免将收缩压强化降至140 mm Hg以下。
  • 对急性缺血性卒中升高的血压,是否干预或任其自然下降需个体化权衡。

局限性

  • 获得必要随机证据存在挑战,尚需随机试验明确血压管理策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with acute ischaemic stroke often present with elevated blood pressure. Evidence has emerged that challenges the longstanding recommendation across clinical guidelines that blood pressure should be controlled to a systolic pressure of less than 185 mm Hg before initiating reperfusion therapy in these patients. RECENT: developments Major clinical trials (INTERACT4, MR-ASAP, and RIGHT-2) and an observational study (TRUTH) indicate that intensively lowering blood pressure before initiating reperfusion therapy for acute ischaemic stroke is associated with increased risk of death and disability. Similar evidence has reshaped our approach to blood pressure management in patients who receive successful endovascular thrombectomy for acute ischaemic stroke from large-vessel occlusion. The underlying mechanisms of cerebral ischaemia are likely to involve alterations in cerebral blood flow through collateral vessels and the microcirculation. WHERE: next? Current evidence underscores the harms of more intensive lowering of blood pressure to a systolic target of less than 140 mm Hg both before and after reperfusion therapy for acute ischaemic stroke. Despite the challenges in obtaining the necessary randomised evidence, such efforts are now required to establish whether elevated blood pressure should be controlled at all with this disease or left to decrease naturally.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Song L, Mao Y, Sandset EC, et al. Early blood pressure management in acute ischaemic stroke before and after reperfusion treatment. Lancet Neurol. 2026. PMID: 41579906. doi:10.1016/S1474-4422(25)00378-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。